Valsartan (Page 6 of 7)

14.2 Heart Failure

The Valsartan Heart Failure Trial (Val-HeFT) was a multinational, double-blind study in which 5,010 patients with NYHA class II (62%) to IV (2%) heart failure and LVEF < 40%, on baseline therapy chosen by their physicians, were randomized to placebo or valsartan (titrated from 40 mg twice daily to the highest tolerated dose or 160 mg twice daily) and followed for a mean of about 2 years. Although Val-HeFT’s primary goal was to examine the effect of valsartan when added to an ACE inhibitor, about 7% were not receiving an ACE inhibitor. Other background therapy included diuretics (86%), digoxin (67%), and beta-blockers (36%). The population studied was 80% male, 46% 65 years or older and 89% Caucasian. At the end of the trial, patients in the valsartan group had a blood pressure that was 4 mmHg systolic and 2 mmHg diastolic lower than the placebo group. There were two primary end points, both assessed as time to first event: all-cause mortality and heart failure morbidity, the latter defined as all-cause mortality, sudden death with resuscitation, hospitalization for heart failure, and the need for intravenous inotropic or vasodilatory drugs for at least 4 hours. These results are summarized in the following table.

CI = Confidence Interval


(N = 2,499)


(N = 2,511)

Hazard Ratio

(95% CI *)



All-cause mortality






(0.90 to 1.15)


HF morbidity






(0.79 to 0.97)


Although the overall morbidity result favored valsartan, this result was largely driven by the 7% of patients not receiving an ACE inhibitor, as shown in the following table.

Without ACE Inhibitor

With ACE Inhibitor


(N = 181)


(N = 185)


(N = 2,318)


(N = 2,326)

Events (%)

77 (42.5%)

46 (24.9%)

724 (31.2%)

677 (29.1%)

Hazard ratio (95% CI)

0.51 (0.35, 0.73)

0.92 (0.82, 1.02)




The modest favorable trend in the group receiving an ACE inhibitor was largely driven by the patients receiving less than the recommended dose of ACE inhibitor. Thus, there is little evidence of further clinical benefit when valsartan is added to an adequate dose of ACE inhibitor.

Secondary end points in the subgroup not receiving ACE inhibitors were as follows.


(N = 181)


(N = 185)

Hazard Ratio

(95% CI)

Components of HF morbidity

All-cause mortality

49 (27.1%)

32 (17.3%)

0.59 (0.37, 0.91)

Sudden death with resuscitation

2 (1.1%)

1 (0.5%)

0.47 (0.04, 5.20)

CHF therapy

1 (0.6%)

0 (0.0%)

CHF hospitalization

48 (26.5%)

24 (13.0%)

0.43 (0.27, 0.71)

Cardiovascular mortality

40 (22.1%)

29 (15.7%)

0.65 (0.40, 1.05)

Non-fatal morbidity

49 (27.1%)

24 (13.0%)

0.42 (0.26, 0.69)

In patients not receiving an ACE inhibitor, valsartan-treated patients had an increase in ejection fraction and reduction in left ventricular internal diastolic diameter (LVIDD).

Effects were generally consistent across subgroups defined by age and gender for the population of patients not receiving an ACE inhibitor. The number of black patients was small and does not permit a meaningful assessment in this subset of patients.


Valsartan tablets USP, 80 mg are available as pink, film-coated, unscored, round, convex tablets, debossed “7432” on one side and “TV” on the other side.

Bottles of 30 NDC 54868-6458-0

Valsartan tablets USP, 160 mg are available as orange, film-coated, unscored, oval-shaped tablets, debossed “7433” on one side and “TEVA” on the other side.

Bottles of 30 NDC 54868-6452-0

Valsartan tablets USP, 320 mg are available as brown, film-coated, unscored, oval-shaped tablets, debossed “7434” on one side and “TEVA” on the other side.

Bottles of 30 NDC 54868-6453-0

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Protect from moisture.

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).


Information for Patients

Pregnancy: Female patients of childbearing age should be told about the consequences of exposure to valsartan during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.

All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.

Sellersville, PA 18960

Rev. J 12/2014


Read the Patient Information that comes with valsartan tablets before you take them and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about valsartan tablets, ask your doctor or pharmacist.

What is the most important information I should know about valsartan tablets?

Valsartan tablets can cause harm or death to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant while taking valsartan tablets, tell your doctor right away.

What are valsartan tablets?

Valsartan tablets are a prescription medicine called an angiotensin receptor blocker (ARB). It is used in adults to:

•lower high blood pressure (hypertension) in adults and children, 6 to 16 years of age.•treat heart failure in adults. In these patients, valsartan tablets may lower the need for hospitalization that happens from heart failure.

Valsartan tablets are not for children under 6 years of age or children with certain kidney problems.

High Blood Pressure (Hypertension). Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. Valsartan tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower your blood pressure lower your chance of having a stroke or heart attack.

High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to stroke, heart attack, heart failure, kidney failure and vision problems.

Heart Failure occurs when the heart is weak and cannot pump enough blood to your lungs and the rest of your body. Just walking or moving can make you short of breath, so you may have to rest a lot.

What should I tell my doctor before taking valsartan tablets?

Tell your doctor about all your medical conditions including whether you:

•have any allergies. See the end of this leaflet for a complete list of ingredients in valsartan tablets.•have a heart condition•have liver problems•have kidney problems•are pregnant or planning to become pregnant. See “What is the most important information I should know about valsartan tablets?”•are breast-feeding. It is not known if valsartan passes into your breast milk. You and your doctor should decide if you will take valsartan tablets or breast-feed, but not both. Talk with your doctor about the best way to feed your baby if you take valsartan tablets.•have ever had a reaction called angioedema, to another blood pressure medicine. Angioedema causes swelling of the face, lips, tongue and/or throat, and may cause difficulty breathing.

Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Especially tell your doctor if you take:

•other medicines for high blood pressure or a heart problem•water pills (also called “diuretics”)•potassium supplements. Your doctor may check the amount of potassium in your blood periodically•a salt substitute. Your doctor may check the amount of potassium in your blood periodically•Non-steroidal anti-inflammatory drugs (like ibuprofen or naproxen)•certain antibiotics (rifamycin group), a drug used to protect against transplant rejection (cyclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of valsartan.•Lithium, a medicine used in some types of depression

Know the medicines you take. Keep a list of your medicines with you to show to your doctor and pharmacist when a new medicine is prescribed. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.

How should I take valsartan tablets?

•Take valsartan tablets exactly as prescribed by your doctor.•For treatment of high blood pressure, take valsartan tablets one time each day, at the same time each day.•If your child cannot swallow tablets, or if tablets are not available in the prescribed strength, your pharmacist will mix valsartan tablets as a liquid suspension for your child. If your child switches between taking the tablet and the suspension, your doctor will adjust the dose as needed. Shake the bottle of suspension well for at least 10 seconds before pouring the dose of medicine to give to your child.•For adult patients with heart failure, take valsartan tablets two times each day, at the same time each day. Your doctor may start you on a low dose of valsartan tablets and may increase the dose during your treatment.•Valsartan tablets can be taken with or without food.•If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time.•If you take too many valsartan tablets, call your doctor or Poison Control Center, or go to the nearest hospital emergency room.

What are the possible side effects of valsartan tablets?

Valsartan tablets may cause the following serious side effects:

Injury or death to an unborn baby. See “What is the most important information I should know about valsartan tablets?

Low Blood Pressure (Hypotension). Low blood pressure is most likely to happen if you also take water pills, are on a low-salt diet, get dialysis treatments, have heart problems, or get sick with vomiting or diarrhea. Lie down, if you feel faint or dizzy. Call your doctor right away.

Kidney problems. Kidney problems may get worse if you already have kidney disease. Some patients will have changes on blood tests for kidney function and may need a lower dose of valsartan tablets. Call your doctor if you get swelling in your feet, ankles, or hands, or unexplained weight gain. If you have heart failure, your doctor should check your kidney function before prescribing valsartan tablets.

The most common side effects of valsartan tablets used to treat people with high blood pressure include:

•headache•dizziness•flu symptoms•tiredness•stomach (abdominal) pain

Side effects were generally mild and brief. They generally have not caused patients to stop taking valsartan tablets.

The most common side effects of valsartan tablets used to treat people with heart failure include:

•dizziness•low blood pressure•diarrhea•joint and back pain•tiredness•high blood potassium

Tell your doctor if you get any side effect that bothers you or that does not go away.

These are not all the possible side effects of valsartan tablets. For a complete list, ask your doctor or pharmacist.

How do I store valsartan tablets?

•Store valsartan tablets at room temperature between 20° to 25°C (68° to 77°F).•Keep valsartan tablets in a closed container in a dry place.•Store bottles of valsartan suspension at room temperature less than 86ºF (30ºC) for up to 30 days, or refrigerate between 35ºF to 46ºF (2ºC to 8ºC) for up to 75 days.•Keep valsartan tablets and all medicines out of the reach of children.

General information about valsartan tablets

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use valsartan tablets for a condition for which they were not prescribed. Do not give valsartan tablets to other people, even if they have the same symptoms you have. They may harm them.

This leaflet summarizes the most important information about valsartan tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about valsartan tablets that is written for health professionals.

For more information about valsartan tablets, ask your pharmacist or doctor, or call 1-888-838-2872.

What are the ingredients in valsartan tablets USP?

Active ingredient: valsartan

Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, iron oxide yellow, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol — part. hydrolyzed, talc, and titanium dioxide. In addition, the 80 mg tablets and 160 mg tablets contain iron oxide red; and the 320 mg tablets contain iron oxide red and iron oxide black.

Sellersville, PA 18960

Rev. B 12/2014

Distributed by:
Physicians Total Care, Inc.
Tulsa, OK 74146

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.